Not long ago, the FDA announced there's no longer a shortage of Ozempic, Wegovy, Zepbound or similar drugs used for weight ...

Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and ...

Now, Eli Lilly, the largest pharmaceutical company in the world in terms of market capitalisation, has launched its own version of the magic drug. Tirzepatide, or Mounjaro, as the company is ...

Eli Lilly may look at manufacturing its weight-loss drug Mounjaro in India in future as it expands its global footprint, CEO David Ricks, who is visiting the country, has said. His comments come ...

In short, the reason is that Eli Lilly launched Mounjaro and Zepbound three years ago [2022 and 2023, respectively], and both of these medications have competitive advantages over Novo Nordisk's ...

Mounjaro, a weight loss drug launched by Eli Lilly in India, could be a game-changer and has been making waves lately. Here's what you need to know. Amy Schumer has praised weight loss drug ...

the approval of Omvoh for Crohn's disease in March 2025 exemplifies Eli Lilly's successful product diversification strategy. The ongoing international expansion plans, particularly for Mounjaro ...

In Q4, Eli Lilly posted revenue of $13.5 billion, driven by demand for Zepbound and Mounjaro, up 45% from the same period a year ago. It also saw net income of $4.4 billion in Q4, compared with a ...

Mounjaro and Zepbound are Eli Lilly's largest sources of growth, but there is much more to the company. Over the last couple of years, the pharmaceutical sector has captivated investors thanks in ...

Furthermore, the approval of Omvoh for Crohn's disease in March 2025 exemplifies Eli Lilly's successful product diversification strategy. The ongoing international expansion plans, particularly for ...

One of the highlights of Eli Lilly's third-quarter results was the rapid uptake of new type 2 diabetes therapy Mounjaro, which added more than $97 million in US sales alone in what has been ...